Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. (GLSI) Market Cap

Greenwich LifeSciences, Inc. has a market capitalization of $327.9M.

Financials based on reported quarter end 2025-09-30

Price: $23.67

โ–ผ -1.27 (-5.09%)

Market Cap: 327.94M

NASDAQ ยท time unavailable

CEO: Snehal S. Patel

Sector: Healthcare

Industry: Biotechnology

IPO Date: 2020-09-25

Website: https://greenwichlifesciences.com

Greenwich LifeSciences, Inc. (GLSI) - Company Information

Market Cap: 327.94M ยท Sector: Healthcare

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Analyst Sentiment

83%
Strong Buy

Based on 2 ratings

Analyst 1Y Forecast: $50.00

Average target (based on 1 sources)

Consensus Price Target

Low

$50

Median

$50

High

$50

Average

$50

Potential Upside: 111.2%

Price & Moving Averages

Loading chart...

Fundamentals Overview

Loading fundamentals overview...

๐Ÿ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-09-30

"GLSI reported minimal revenue of $0 for the quarter ended September 30, 2025, reflecting a challenging operating environment, with a net loss of approximately $4.15M. The company does not generate free cash flow, indicating potential liquidity issues. Total assets stand at $3.81M, with total liabilities of $1.62M, resulting in total equity of $2.18M. Its financial stability is somewhat bolstered by a net debt position of -$3.81M, suggesting it has a cash surplus over liabilities. Despite a lack of revenue, the stock price increased by over 128% over the past year, signaling strong market sentiment and potential speculative interest. However, without revenue generation or positive cash flow, long-term sustainability remains in question. Continued monitoring of operational performance and financial health will be critical for potential investors."

Revenue Growth

Neutral

No revenue generated, indicating a pre-revenue status.

Profitability

Neutral

Significant net loss of $4.15M reflects poor profitability.

Cash Flow Quality

Neutral

Negative operational cash flow indicates liquidity challenges.

Leverage & Balance Sheet

Neutral

Strong equity position with cash surplus over liabilities.

Shareholder Returns

Good

Strong price appreciation of 128.27% over the past year.

Analyst Sentiment & Valuation

Fair

Current price substantially above target consensus, suggesting speculative valuation.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Loading financial data and tables...
๐Ÿ“

SEC Filings (GLSI)

ยฉ 2026 Stock Market Info โ€” Greenwich LifeSciences, Inc. (GLSI) Financial Profile